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Abstract
Objectives. To systematically review and meta-analyse evidence on the effectiveness of the TNF-a
inhibitors when used sequentially.
Methods. Systematic review of comparative and single-arm observational studies. Data were synthesized
using random-effects meta-analysis. Treatment effects were estimated using four outcome measures from
the included studies: European League Against Rheumatism (EULAR) and ACR20 response rates and
mean improvement in disease activity score-28 (DAS-20) and HAQ. The effect of other factors was
explored via meta-regression and sub-group analyses.
Results. Twenty studies comprising 2705 patients were included in the analysis. All studies were obser-
vational and most had no control group. Therefore, our primary analysis considered patient changes from
baseline. The mean percentage of ACR20 responders was 60.8% (95% CI 53.8, 67.4), EULAR responders
70.5% (95% CI 63.7, 76.6), mean overall improvement in DAS-28 scores was 1.53 (95% CI 1.25, 1.80) and
in HAQ scores was 0.25 (95% CI 0.11, 0.40). Four studies made comparisons with patients who received
TNF-a inhibitors for the first time. Response rates associated with sequential TNF-a inhibitor treatment
were lower than for first-time use.
Conclusions. Sequential TNF-a inhibitor use is likely to lead to treatment benefit in terms of the signs and
symptoms of disease and physical function. There is also some evidence to suggest that the probability of
achieving a response is lower, and the average magnitude of response is lower than the first use. Further
evidence from randomized controlled trials is required to confirm and further quantify the role specific
anti-TNF-a agents have when used sequentially.
Key words: Rheumatoid arthritis, Systematic review, Meta-analysis, TNF-a inhibitors, Sequential.
Introduction
RA is the most common form of inflammatory arthritis with
prevalence estimated at 0.8% of the population [1] and
incidence between 1.5 per 10 000 for males and 3.6 per
10 000 for females in the UK. [2] Although joint destruction
can be painful and disabling, RA is also a systemic dis-
ease often affecting extra-articular tissues throughout the
body. RA imposes a substantial cost burden both to
health services and to the wider economy, particularly
due to the fact that many patients are unable to continue
working [3].
Biologic treatments are used when conventional
DMARDs such as MTX cannot control RA synovitis. The
efficacy of TNF-a inhibitors—infliximab, adalimumab
and etanercept—the first biologics used in RA, has
been established in randomized controlled trials (RCTs)
[4–6] and confirmed in meta-analyses [7]. There is
also evidence that they may be cost-effective when
conventional DMARDs are insufficient [8, 9]. Newer
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biologics—rituximab, abatacept and tocilizumab—also
have proven efficacy [10, 11], though their cost-effective-
ness is more controversial.
A substantial minority of RA patients stop taking their
first TNF-a inhibitor due to intolerance, lack of response
(primary inefficacy) or loss of response (secondary ineffi-
cacy). Treatment options in these patients comprise
switching to a second TNF-a inhibitor, alternative bio-
logics such as rituximab and reverting to non-biological
treatments. Biologics are high-cost treatments. It is, there-
fore, of crucial importance that policy makers and
rheumatologists alike consider the relative effectiveness
and cost-effectiveness of switching TNF-a inhibitors com-
pared with these alternative strategies.
There is uncertainty about the relative efficacy of TNF-a
inhibitors with first and subsequent use. As there are gen-
etic response predictors for some TNF-a inhibitors in RA
[12, 13], there might be a class effect with patients failing
to respond to one TNF-a inhibitor failing to respond to
other agents in the class. Recent analyses of the cost-
effectiveness of sequential TNF-a inhibitor therapy have,
therefore, assumed efficacy is equivalent to first use
[13, 14]. As a consequence, direct evidence is needed
about the effectiveness of TNF-a inhibitor switching to
inform clinical and drug reimbursement decision makers.
We have, therefore, estimated the treatment effect of
the TNF-a inhibitors, both as a class and as individual
agents, when used sequentially. The analysis is based
on evidence identified from a systematic review and con-
siders the most widely reported outcome measures in RA:
the HAQ and disease activity score (DAS) measures, and
the ACR and European League Against Rheumatism
(EULAR) response criteria. The analysis also explores rea-
sons for heterogeneity in study results, including reason
for switching (intolerance, primary inefficacy or secondary
inefficacy) and the TNF-a inhibitor that patients switched
from or switched to.
Methods
Systematic review
The aim of the review was to identify all articles published
in peer-reviewed journals that reported the clinical effect-
iveness of either infliximab, adalimumab or etanercept in
RA patients that had previously been treated with at least
one TNF-a inhibitor.
We conducted comprehensive searches of electronic
databases (Cochrane Library, MEDLINE, EMBASE and
NHS Database of Reviews of Effectiveness). Reference
lists for identified studies were hand searched. A combin-
ation of free-text and thesaurus search terms were em-
ployed to specify both the relevant population and
interventions (see appendix 1 for details, available as sup-
plementary data at Rheumatology Online). Searches were
conducted to cover the period from January 2001 to
October 2009.
Studies were included if they considered RA patients
that had withdrawn from either infliximab and/or etaner-
cept and/or adalimumab (but not all three) and had been
switched to a different TNF-a inhibitor. Studies of patients
with other conditions such as juvenile arthritis, Crohn’s
disease, PsA or other forms of SpA were excluded
unless RA patients could be distinguished in the results.
Studies reporting switches to anakinra, abatacept or ritux-
imab were not included. At least one of the following out-
come measures that reflect the signs, symptoms and
impact on physical function of RA had to be reported for
a study to be included: ACR, EULAR, HAQ or DAS/
DAS-28. We did not consider radiographic outcome
measures.
Identified studies were selected for review by one of us
(A.J.W.) based on the title and abstract if available.
Articles selected were then assessed against the inclusion
criteria on the basis of the full study reports. In addition to
the criteria given above, several studies were excluded at
this stage because they replicated data reported in other
studies included in the review.
Data from included studies were extracted indepen-
dently by two of the authors with any disagreements
resolved by consensus. We recorded the TNF-a inhibitor
being investigated and the TNF-a inhibitor patients had
switched from. The reason for switching was categorized
as intolerance or adverse events, primary inefficacy (a fail-
ure to achieve a clinical response from the start of treat-
ment), secondary inefficacy (a loss of response over time
in patients that had originally achieved primary response)
and other. Outcome data were recorded that consisted of
number of patients, proportions of responders in case of
ACR and EULAR scores and for continuous outcome
measures DAS-28 and HAQ, means and standard errors
if available. Otherwise S.D.s, medians or inter-quartile
ranges were noted. Where studies reported outcomes at
multiple time points after switching treatments, data for
each time point were extracted. These outcome measures
were recorded for whole cohorts described in each of the
included studies as well as for sub-groups of patients
defined by sequence of the TNF-a inhibitor and by
reason for switching. Other patient characteristics ex-
tracted from the selected papers included mean age, per-
centage of females, percentage of patients classified as
being RF+, mean disease duration in years, mean number
of previous DMARDs, mean duration of previous biologic
treatment in months and follow-up time in weeks.
Meta-analysis
Each of the four outcome measures—ACR, EULAR, DAS
and HAQ—were considered separately in the analysis, al-
though similar analytic methods were utilized; different
measures of effect size were used for the categorical
and continuous data. We found that many studies re-
ported only ACR20, not ACR50/70/90, and we, therefore,
limit discussion to this outcome measure.
Random-effects meta-analysis models were used from
the outset due to the known clinical heterogeneity be-
tween studies. Where data on sub-groups only were avail-
able, a fixed-effects meta-analysis was carried out to
obtain the overall outcome for the whole cohort. For
non-comparative studies, the meta-analysis for the
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binary response data was carried out using the log-odds
of being classed as a responder (transformed back to a
proportion for interpretation). The effect size for the con-
tinuous outcomes was the change from baseline score
(improvement in DAS-28 or HAQ scores). Missing data
were calculated or imputed for the continuous outcomes
where necessary (in particular, for the change from base-
line values and the associated S.E.s) using both
within-study [15] and across-study imputation methods
[16] (see appendix 2 for details, available as supplemen-
tary data at Rheumatology Online).
Initially, meta-analyses were conducted treating all
TNF-a inhibitors as a class (i.e. assuming equal effective-
ness). Variability between the studies was assessed using
the I2-statistic, which can take values between 0 and
100% where high values indicate strong heterogeneity.
Meta-regression models [17] were then developed with
the aim of trying to explain heterogeneity using the
study-level demographic covariates of mean age, per-
centage of females and baseline characteristics that
included the percentage of RF+ patients, mean disease
duration, mean number of previous DMARDs and the
mean duration of previous biologic treatments.
Follow-up time was also considered. Sub-group analyses
and meta-regressions were then carried out to determine
whether there were differences in outcome according to
the type and sequence of TNF-a inhibitor received—ada-
limumab, etanercept or infliximab—or according to the
reason for switching to another treatment—primary ineffi-
cacy, secondary inefficacy, inefficacy, intolerance or
other.
Data estimating the comparative effect of sequential
TNF-a inhibitors use vs first-line use were extracted
where reported. Meta-analysis was used to pool the re-
sults from multiple studies. As for the non-comparative
analyses, where the S.E.s of the differences in outcome
from baseline were not reported, it was necessary to
use imputation methods. Studies that reported data on
rituximab controls are not included in the meta-analysis
but reported separately.
Publication bias was assessed using funnel plots and
Eggers test. All analyses were conducted in Stata v11.0
(StataCorp LP, TX, USA), with a significance level of 5%.
No adjustments were made for multiple testing.
Results
Systematic review
Study characteristics. Searches resulted in 453 unique
references. A total of 67 studies were identified for
review, and of these a total of 20 [18–37] were eligible
for inclusion. These provided data on a total of 2705 pa-
tients that received sequential TNF-a inhibitor treatment.
Table 1 provides details related to treatments in the
included studies, whereas Table 2 lists reported outcome
measures indicating also those in comparator groups
where available. Fifteen of the studies have no comparator
group. Four studies make comparisons with other
cohorts of patients taking a first anti-TNF-a and who
may or may not include the group that subsequently
switched [18, 20, 34, 37]. One of these studies [20] in-
cludes data on over 800 switching patients and over
5000 patients receiving their first TNF-a inhibitor. One
other study makes comparisons with patients that
switched to rituximab [25]. Clearly, such comparisons
must be treated with caution owing to the observational
nature of these studies. One of the identified studies is an
RCT [38] and this is an open-label, pilot study (n = 28).
However, this study included patients who responded to
the first TNF-a inhibitor and were then randomized. We
acknowledge that this study is different and we exclude
it from the comparative analysis. Sensitivity analysis
showed that excluding this study from the single-arm
analysis did not have any impact on the conclusions.
Many of the identified studies are relatively small;
14 (61%) have fewer than 50 patients and 4 (17%) have
fewer than 20 patients.
Follow-up was typically 12–24 weeks from baseline
(range 2–96 weeks). In total, 10 studies reported ACR20
response rates [19–22, 26, 30, 34–37], 12 reported EULAR
response rates [18–20, 22–24, 27, 30, 31, 33–35],
13 DAS-28 improvement [18–20,22–25,27,32–35,37] and
8 HAQ improvement [19, 20, 27, 31, 33, 35]. Three studies
reported all four outcomes of interest [19, 20, 35]. Details
are shown in Table 2.
Table 1 also shows that the included studies reported
data on patients that switched from their first TNF-a in-
hibitor for a variety of reasons. Sub-groups of patients
were reported according to the reason for discontinuation:
primary inefficacy; secondary inefficacy; primary or sec-
ondary inefficacy or adverse events.
Characteristics of patients in studies. The mean and
range of the reported patient characteristics (weighted
by sample size) in the included studies are reported in
Table 3. Most studies reported the mean (or median)
age and gender of participants. Reporting of other poten-
tially relevant baseline characteristics was less
widespread.
Meta-analysis results
ACR20. The proportion of ACR20 responders within the
studies ranged from 45 to 76%. The pooled response
rate was 60.8% (95% CI 53.8, 67.4), suggesting that at
least half of patients switching to an alternative TNF-a in-
hibitor achieved a minimum of an ACR20 response
(Fig. 1a). There was a high degree of variability in the esti-
mated proportion due to heterogeneity between the stu-
dies (I2 = 77.5), which could not be accounted for by patient
demographic or baseline characteristics. There was no
significant difference identified in estimates by sub-group
based either on the sequence of TNF-a inhibitor or on
the reason for switching from one anti-TNF to another.
EULAR. The proportion of EULAR responders within the
studies ranged from 47 to 85% (Fig. 1b), and the pooled
effect size was estimated to be 70.5% (95% CI 63.7,
76.6). There was a high degree of variability in the esti-
mated response rate due to heterogeneity between
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studies (I2 = 86.3%). No significant effect of baseline char-
acteristics, demographic variables, anti-TNF sequence or
reason for switching was found that would explain this
heterogeneity.
DAS-28. Change from baseline DAS-28 ranged from
0.98 to 2.4. The overall estimate of the reduction in
DAS-28 score (from baseline) was 1.53 (95% CI 1.25,
1.80; Fig. 1c), and the analysis showed a high degree of
variability in effect sizes (I2 = 94.8%). The duration of the
disease had a significant effect on patients’ DAS-28
responses, giving additional reduction in DAS-28 score
by 0.157 (95% CI 0.243, 0.072, P = 0.004) per add-
itional year.
TABLE 1 Characteristics of included studies
Study n
Failed
anti-TNF, n New anti-TNF
Reason for
switching, %
Time point,
weeks
Bennett et al. [18] 26 INF, ETA, AKA ADA PIE (31), SIE (50) 34a
Bingham et al. [19] 188 INF ETA PIE (15), SIE (85) 16
Bombardieri et al. [20] 810 ETA (168) ADA PIE (24), SIE (31), AE (30) 12
INF (541) ADA PIE (30), SIE (19), AE (29)
ETA and INF (120) ADA IE/AE
Buch et al. [21] 25 INF ETA PIE 12
Buch et al. [22] 7 INF ETA PIE (36), SIE (40), AE (24) 12
Cohen et al. [23] 30 INF (18), ETA (12) ETA, INF PIE (76), AE (4) 12
Di Poi et al. [24] 18 INF ETA PIE (61), SIE (39) 42
Finckh et al. [25] 66 Unspecified Unspecified IE 24
Haraoui et al. [26] 22 INF ETA IE/AE 6, 12
Hjardem et al. [27] 156 INF (130), ETA (7), ADA (19) Unspecified IE (46), AE (31) 12
Hyrich et al. [28] 331 ETA, INF, ADA ETA, INF, ADA IE 52
Iannone et al. [29] 37 INF ETA AE (100) 8, 16, 24
Karlsson et al. [30] 337 Unspecified Unspecified IE (41), AE (41) 12
Koike et al. [31] 411 INF ETA IE/AE 24
Laas et al. [32] 26 INF ETA IE (77), AE (23) 12, 24, 36
Navarro-Sarabia et al. [33] 83 Unspecified Unspecified IE (58), AE (29) unclear
Nikas et al. [34] 24 INF ADA IE (38), AE (62) 48
Van der Bijl et al. [35] 41 INF ADA PIE (37), SIE (51), AE (12) 16
van Vollenhoven et al. [36] 31 ETA (18), INF (13) INF, ETA IE (77), AE (11) 12
Wick et al. [37] 36 INF (27), ETA (9) ADA SIE 12, 24
aThis was the mean time of follow-up, not a set time from baseline. INF: infliximab; ETA: etanercept; ADA: adalimumab; AKA:
anakinra; IE: inefficacy (primary or secondary); PIE: primary inefficacy; SIE: secondary inefficacy; AE: adverse event.
TABLE 2 Reported outcomes in selected studies
Study
Outcomes reported
ACR EULAR DAS-28 HAQ
Bennett et al. [18] 3a 3a 3a
Bingham et al. [19] 3 3 3 3
Bombardieri et al. [20] 3a 3a 3a 3a
Buch et al. [21] 3
Buch et al. [22] 3 3 3
Cohen et al. [23] 3 3
Di Poi et al. [24] 3 3
Finckh et al. [25] 3b
Haraoui et al. [26] 3 3
Hjardem et al. [27] 3 3
Hyrich et al. [28] 3
Iannone et al. [29] 3
Karlsson et al. [30] 3 3
Koike et al. [31] 3
Laas et al. [32] 3
Navarro-Sarabia et al. [33] 3 3 3
Nikas et al. [34] 3a 3a 3a
Van der Bijl et al. [35] 3 3 3 3
Van Vollenhoven et al. [36] 3
Wick et al. [37] 3a 3a
Also given are reported data for comparator group that
had: anot previously received anti-TNF-a; breceived
rituximab.
TABLE 3 Characteristics of patient populations in included
studies
Characteristic Studies, n
Weighted
mean
Range
of study
means
Mean age, years 19 55.0 47.1–58.0
Female, % 18 80.1 63.6–92.0
RF+, % 13 71.4 44.0–97.0
Mean disease
duration, years
14 11.6 8.0–16.6
Mean number of
previous DMARDs
10 4.6 3.4–5.8
Mean previous biologic
duration, months
10 14.9 9.0–25.2
2316 www.rheumatology.oxfordjournals.org
Suzanne Lloyd et al.
FIG. 1 Forest plots showing response rates on the ACR20 scale (a), response rates on EULAR scale (b), response to
treatment recorded by change in DAS-28 scores compared with baseline scores (c) and reduction in HAQ scores (d).
Weights are from random-effects analysis.
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FIG. 1 Continued
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HAQ. HAQ change ranged from increase by 0.15 to
decrease by 0.48. The pooled reduction in HAQ score
from baseline was 0.25 (95% CI 0.11, 0.40; Fig. 1d).
Heterogeneity was also an issue in these studies with
I2 = 93.5%. None of the demographic variables, baseline
characteristics or sub-groups of reason for switching or
anti-TNF sequence had a significant effect on the change
from baseline scores.
Comparative meta-analysis
Four studies [18, 20, 34, 37] reported data comparing out-
comes of patients receiving sequential TNF-a inhibitors
with those receiving the treatment for the first time.
Three of these studies [20, 34, 37] reported ACR20 out-
comes, three [18, 20, 34] reported EULAR response rates
and all four reported improvement in DAS-28. Only two
studies reported information on HAQ improvement,
[18, 20] and one [18] was excluded due to lack of data.
A random-effects meta-analysis comparing response
rates for sequential use with first-time use produced an
odds ratio of 0.65 (95% CI 0.56, 0.76) for ACR20 data and
0.60 (95% CI 0.50, 0.71) for EULAR outcomes. Meta-
analysis of improvement in DAS-28 gave weighted mean
difference of 0.37 (95% CI 0.57, 0.17). Data from one
study [20] showed mean difference in HAQ improvement
of 0.07 (95% CI 0.11, 0.03). All the above results
consistently show superior response in patients receiving
anti-TNF-a for the first time. This may, in part, be a selec-
tion bias since switchers are by definition, first biologic
treatment failures.
One study reported comparative data for patients who
switched to second or third TNF-a inhibitor with patients
who switched to rituximab after failing at least one TNF-a
inhibitor [25]. The estimated difference in DAS-28 im-
provement between TNF-a inhibitor switchers and rituxi-
mab switchers was 0.63 (95% CI 1.14, 0.12). None of
the tests for publication bias for any of the analyses was
statistically significant.
Discussion
This meta-analysis shows that patients who fail one TNF-a
inhibitor due to intolerance, inefficacy or loss of efficacy
may still benefit from switching to another drug from this
group. However, those studies that compared outcomes
for sequential with initial TNF-a inhibitor use showed lower
response rates. More evidence is needed, particularly
from RCTs, to define the effectiveness of switching. This
is happening with new TNF inhibitors; for example, an
RCT of switching with golimumab—a recently licensed
TNF-a inhibitor—showed 37% of patients achieved an
ACR20 response compared with 18% receiving placebo
[39]. The only RCT [38] identified within the search for the
purpose of this review, reported outcomes of patients who
at least partially responded to etanercept and then were
randomized to either switch to infliximab or to continue
etanercept. The odds ratio for ACR20 response was
3.14 (95% CI 0.94, 10.30) and the difference in DAS-28
improvement was 0.90 (95% CI 0.14, 1.94). Both results
favoured switching to infliximab but were not statistically
significant.
Our evidence synthesis has several limitations. Most
importantly, all the evidence was based on observational
studies. Some studies reported comparative data in which
controls were patients receiving biologic treatments for
the first time. In these studies, a degree of selection bias
is inevitable as patients who fail a TNF-a inhibitor will have
worse prognoses and are likely to show limited responses
to all treatments.
There are a number of other limitations. Many studies
did not report S.E.s and these needed to be imputed.
There were also inconsistencies in reporting outcomes in
some studies that had to be excluded, thus depleting the
data available for meta-analysis. Finally, there was
marked heterogeneity between studies. This variation
was not explained by the study-level covariates used in
the sub-group analyses or meta-regressions.
We conclude that there is evidence that RA patients
who fail to respond to one TNF inhibitor will show a sig-
nificant response to a second agent. This view is sup-
ported by other analyses of the available literature
[5, 10, 40]. However, the relative merits of switching
TNF-a inhibitors compared with starting another biologic
such as rituximab is controversial; there is some evidence,
notably from Finckh et al. [25], that starting rituximab is
more effective and this could potentially be more
cost-effective. Further RCTs and associated economic
evaluations are needed to clarify the role of sequential
use of TNF-a inhibitors in RA. However, the value of iden-
tifying and synthesizing this evidence should be recog-
nized in the light of the requirements of decision makers,
both at the individual patient and drug reimbursement
level, at the current time. Bodies such as the National
Institute for Health and Clinical Excellence in England
and Wales, have a need to issue guidance on sequential
use of TNF-a inhibitors despite the shortcomings in the
available data.
Rheumatology key messages
. Patients are likely to benefit from sequential TNF-a
inhibitor treatment.
. The average magnitude of benefit is unlikely to be
as great as in TNF-a inhibitor naı¨ve patients.
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